Journal article
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): A stratified, biopsy-driven, multi-centre, randomised, open label, controlled clinical trial - 16 week outcomes
- Abstract:
-
Background:
Expand abstract
Although targeted biological treatments have transformed the outlook for patients with rheumatoid arthritis, 40% of patients show poor clinical response, which is mechanistically still unexplained. Because more than 50% of patients with rheumatoid arthritis have low or absent CD20 B cells—the target for rituximab—in the main disease tissue (joint synovium), we hypothesised that, in these patients, the IL-6 receptor inhibitor tocilizumab would be more eff...
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 600.0KB, Terms of use)
-
- Publisher copy:
- 10.1016/S0140-6736(20)32341-2
Authors
- Publisher:
- Elsevier
- Journal:
- Lancet More from this journal
- Volume:
- 397
- Issue:
- 10271
- Pages:
- 305-317
- Publication date:
- 2021-01-23
- Acceptance date:
- 2020-10-27
- DOI:
- EISSN:
-
1474-547X
- ISSN:
-
0140-6736
- Language:
-
English
- Keywords:
- Pubs id:
-
1151998
- Local pid:
-
pubs:1151998
- Deposit date:
-
2021-01-04
- ARK identifier:
Terms of use
- Copyright holder:
- Humby et al.
- Copyright date:
- 2021
- Rights statement:
- © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record